Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

Please provide your email address to receive an email when new articles are posted on . A post-hoc analysis of 11 trials found upadacitinib and infliximab had the highest symptom improvement rates at ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

INCHEON, South Korea, November 18, 2025--(BUSINESS WIRE)--Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

The Appraisal Committee considered evidence submitted by the manufacturer of infliximab and a review of this submission by the Evidence Review Group (ERG). The manufacturer developed a systematic ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study. Infliximab was the first anti-tumor necrosis ...

Vaughn and colleagues have demonstrated that proactive therapeutic concentration monitoring (TCM) of infliximab in patients with IBD who are in clinical remission might be useful for the ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of infliximab, having considered evidence on the nature of acute exacerbations of severely active ulcerative ...